Episoder
-
In honor of National Family Health History Month in November, we have a special guest. We share the story of an incredible colorectal cancer survivor and health advocate, Marisa Peters, who was a Broadway vocalist and a very healthy, active mom to 3 young boys, yet diagnosed with stage 3 rectal cancer at only 39 years old.
-
This week’s episode is part 3 of 2024 updates focusing on treatment options for metastatic breast cancer. We will cover important details on systemic therapy related to metastatic breast cancer & key toxicities. We are honored to have Dr. Eleonora Teplinsky, a board-certified medical oncologist specializing in breast and gynecologic oncology, as a guest sharing some pearls.
-
Mangler du episoder?
-
This week’s episode is part 2 of 2024 updates focusing on treatment options for localized breast cancer. We will discuss important details on radiation, as well as therapies based on ER/PR/her2 receptor status. We are honored to have Dr. Eleonora Teplinsky, a board-certified medical oncologist specializing in breast and gynecologic oncology, as a guest sharing some pearls.
-
We are continuing our 2024 updates, this week’s episode will be an intro to breast cancer. Today’s will include high yield tips on screening, prevention, ductal carcinoma in situ DCIS, lobular carcinoma in situ LCIS, as well as introduce invasive localized disease.
-
This week’s episode will be discussing our favorite heme/onc board review resources. This is pertinent to new fellows who are starting to think about how to study during fellowship, preparation for ITEs and of course studying for the boards.
-
We are doing a special episode this week to cover some of the key GU abstracts from ESMO 2024. We cover an update on the STAMPEDE prostate cancer trial, SUNNIFORECAST in non-clear cell renal cell carcinoma, SunRISe-4 in bladder cancer, and more.
-
In Part 2 we discuss how to deal with patients of different backgrounds, navigating spiritual & emotional challenges in oncology, tips for physicians who are experiencing moral distress & compassion fatigue, as well as general career advice. We are so honored to have Dr. Janet Abrahm with us who is a national leader in the field of palliative care and a professor at Harvard Medical School.
-
This week’s episode will be focusing on final board review tips. We will go over our highest yield cheat sheet topics, and how we prepared the days leading up to our exam. We took our boards three years ago now, but the stress leading up to the exam is certainly fresh in our minds.
-
In Part 1 we discuss how to explain palliative care to patients, pain and anti-emetic management, non-pharmacologic strategies, and current innovations within palliative care. We are so honored to have Dr. Janet Abrahm here with us who is a national leader in the field of palliative care and a professor at Harvard Medical School.
-
This week’s episode will be repeating our episode on hemophilias with some updates. We will go over all high yield facts regarding both hemophilia A and B for your boards and end with a little bit about acquired hemophilias.
-
This week’s episode will be discussing updates from ASCO 2024 next with the practice changing NADINA trial presented on the Sunday of ASCO by Dr. Christian Blank during the plenary sessions: A multicenter, randomized, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. We discuss the staging and prior standard of treatment for locally advanced melanoma, key findings from NADINA, and how these data may impact clinical practice.
-
Today’s episode is a continuation on fast facts for the IM Board review focusing on the oncology questions. Another 6% of the certifying ABIM test is oncology. While we can’t cover ALL of oncology in just 10 minutes, here are 10 high yield concepts/facts/vignettes you should know walking into your IM Boards.
-
Today’s episode focuses on what you need to know to ace the hematology questions for your 2024 IM boards. 6% of the ABIM exam is hematology which includes erythrocyte, leukocyte and platelet disorders, coagulation disorders, transfusion medicine, and heme malignancies. We discuss some common vignettes & high yield points.
-
This week’s episode will be focusing on infusion reactions - one of the most common calls we get as heme/onc fellows and high yield facts for new fellows as well as boards. We will go over the important details on mechanisms of infusion reaction, class of drugs that most commonly cause infusion reactions, treatment for infusion reactions, and when/how to re-challenge.
-
This week’s episode will be focusing on common topics both for new fellows & residents. We will go over the important details on some clinically important oncologic emergencies including brain metastases, hypercalcemia, cord compression and SVC syndrome.
-
This week’s episode will discuss updates from ASCO 2024 next with the practice changing ADRIATIC trial presented by Dr. Spigel during the plenary: Durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer (LS-SCLC).
-
In light of the new academic year today, we are so excited for this special episode, hosting Dr Shikha Jain, who is the founder of Women in Medicine & a GI oncologist, & involved with ASCO Women's Networking Center. She shares some of her tips for new doctors, and a few for new attendings.
-
Today’s episode is an update on AML (acute myeloid leukemia). In Part 2 we discuss the treatment options for first-line, as well as relapsed/refractory disease. We are so honored to have Dr. Catherine Lai here with us who is Associate Professor and Physician Leader of the Leukemia Clinical Research Unit at UPenn.
-
Today’s episode is an update on AML (acute myeloid leukemia). In Part 1 we discuss the usual presentation, diagnostic work-up, and updates on the classification of AMLs. We are so honored to have Dr. Catherine Lai here with us who is Associate Professor and Physician Leader of the Leukemia Clinical Research Unit at UPenn.
-
This week’s episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam.
- Se mer
